Darinaparsin (Dar) is a more potent cytotoxic arsenical than arsenic trioxide (ATO). We hypothesized that the increased cytotoxicity of Dar may be because of a decreased cytoprotective response. We observed that, unlike ATO, Dar does not induce heme oxygenase-1 (HO-1), even though it induces expression of other nuclear factor (erythroid-derived 2)-like 2 (NRF2)-dependent detoxifying enzymes to a greater extent than ATO, in both cancer cell lines and patient-derived leukemic cells. This strengthens the emerging evidence, showing that response to reactive oxygen species (ROS) is stimuli specific. Dar treatment prevents recruitment of the transcriptional coregulator Brahma-related gene 1 (BRG1) to the HMOX1 promoter, which is required for HMOX1 expression. The inability of Dar to induce HO-1 correlates with arrest in G2/M cell cycle phase and BRG1 phosphorylation. Inhibition of HO-1 increases the toxicity of ATO, but has no effect on Dar-induced apoptosis. Accordingly, the lack of HO-1 induction is involved in Dar's enhanced antileukemic properties. Our data highlight cytoprotective responses mediated by HO-1 and BRG1 as a novel target for enhancing the therapeutic range of arsenicals.
INTRODUCTION
Darinaparsin (Dar; ZIO-101, S-dimethylarsino-glutathione) is a promising new arsenic-based, anticancer drug candidate, which is currently undergoing clinical studies in both hematological malignancies and solid tumors. 1 This organic arsenical, which consists of dimethylarsenic conjugated to glutathione, shows significant activity against multiple cancers in vitro. 2 Another arsenical, arsenic trioxide (ATO), is a proven chemotherapy for acute promyelocytic leukemia (APL), but has substantially reduced antitumor effects at clinically achievable doses in other malignancies. [3] [4] [5] We have shown previously that Dar is a more potent inducer of apoptosis than ATO in various malignant cell lines and is highly active against APL cells. Importantly, Dar has a maximum tolerated dose that is 50-fold higher than ATO in mice and is active against xenograft tumors. 6 However, the mechanisms of its increased antitumor efficacy have not been elucidated.
Oxidative damage is postulated to be a key mechanism by which arsenicals initiate the apoptotic process. [7] [8] [9] [10] [11] [12] Consistent with its increased cytotoxicity, we have reported that Dar induces significantly more superoxide (O 2 -), hydrogen peroxide and oxidative damage than ATO in arsenic-sensitive NB4 and arsenic-resistant AR2 cells. 2 Both ATO and Dar-induced ROS activate the c-Jun NH 2 -terminal kinase/stress-activated protein kinase pathway, leading to apoptosis. 2, 13, 14 However, we have also reported that Dar triggers apoptosis by inducing cellular responses that do not completely overlap with ATO.
1,2 The characterization of similarities versus differences in triggered pathways and intracellular ROS modulation between ATO and Dar have elicited interest among the labs working on arsenic, as we reviewed. 1 We postulate that within the signaling differences lies the mechanism responsible for the enhanced antitumor effect of Dar.
In response to oxidative stress, cells induce an arsenal of protective proteins including the nuclear factor (erythroid-derived 2)-like 2 (NRF2) gene battery, which includes heme oxygenase-1 (HO-1, HMOX1 gene), NAD(P)H:quinone oxidoreductase (NQO1), thioredoxin-reductase-1 (TR1, TXNRD1 gene) and glutamatecysteine ligase regulatory subunit (gGCS). 15 NRF2 is a basic leucine zipper transcription factor that mediates the expression of these key protective enzymes by binding antioxidant response elements (ARE) [16] [17] [18] in the regulatory regions of these genes. Under unstressed conditions, Kelch-like ECH-associated protein 1 confines NRF2 in the cytoplasm, where it is constitutively degraded. [19] [20] [21] In contrast, ROS liberate NRF2 from Kelch-like ECH-associated protein 1, leading to NRF2 translocation and accumulation in the nucleus. 15 Transcriptional regulation of some of these detoxifying enzymes involves a competition between the activator NRF2 and the repressor BTB, and CNC homolog 1 (BACH1) for interaction with their AREs. 22 Of the NRF2 target genes, regulation of HMOX1 expression is unique because it is further regulated by the binding of Brahma-related gene 1 (BRG1, SMARCA4 gene), the catalytic subunit of SWI2/SNF2-like chromatinremodeling complex, to the ARE. 23 Here, we show that Dar selectively fails to induce HO-1 expression in leukemic cell lines in vitro and in APL patient blasts ex vivo, even though it induces the expression of other NRF2 target genes. We provide evidence that Dar prevents BRG1 recruitment to the HMOX1 promoter. We also show that specific inhibition of HO-1 enhances the toxicity of ATO, but not Dar, in 1 leukemic cells. This suggests that the inability of Dar to induce HO-1 expression is partially responsible for the increased pro-apoptotic potential we observe.
MATERIALS AND METHODS

Ethics statement
The patient samples were obtained, collected and used in accordance to the ethical requirements and regulations of the Jewish General Hospital. Informed written consent was obtained from all patients involved.
Cell culture All cells were grown in a humidified chamber at 37 1C with 5% CO 2 . NB4, U937, U266, Kasumi-1, LY8 and HeLa cells were obtained from the american type culture collection (ATCC) and cultured as recommended. Blasts from APL patients were isolated from either peripheral blood or bone marrow (see Supplementary Materials).
Cell viability and caspase-3/7 assay Cell viability and caspase-3/7 activity were assayed using CellTiter-Glo Luminescent Cell Viability Assay and Caspase-Glo 3/7 Assay (Promega, Madison, WI, USA) according to manufacturer's instruction (see Supplementary Materials).
Propidium iodide staining
Quantification of apoptotic cells was performed as previously described 2 (see Supplementary Materials).
Protein quantification
Cells were lysed, whole-cell extracts were run on SDS-polyacrylamide gel electrophoresis followed by western blot analysis (see Supplementary  Table 1 ). Levels of phospho-DNA-PKcs (T2604) were measured by flow cytometry (see Supplementary Materials). NRF2 protein levels were assessed by densitometry using Image J (imagej.nih.gov). The intensity of each NRF2 band is normalized with the corresponding loading control band (GAPDH or H3) and compared with the corresponding nuclear or cytoplasmic control-treated bands, which were given the value of 1. mRNA analysis Total mRNA was isolated by using TRIzol. Complementary DNA were amplified using Taqman or SYBR green technology (see Supplementary  Materials and Supplementary Table 2 ).
Chromatin immunoprecipitations
Chromatin immunoprecipitations (ChIP) were performed as adapted from a previously described method 23 
Statistical analysis
Significance was determined by one-way analysis of variance followed by Newman-Keuls post-tests using Prism version 3.0 (GraphPad software, San Diego, CA, USA). *Po0.05; **Po0.01, ***Po0.001.
RESULTS
Dar is more toxic than ATO and fails to induce HO-1 in various malignant cell lines We have previously shown that Dar induces more apoptosis than ATO in NB4 cells, a model for the study of human APL, and in U937 cells. To expand these observations, we tested the effect of Dar and ATO on six cell lines isolated from various hematological malignancies, including NB4 and U937. Throughout the panel, Dar was more potent at inducing apoptosis, as shown in Figure 1a . We have previously shown that Dar induces more ROS than ATO. 2 We hypothesized that the enhanced cytotoxicity of Dar is because of its inability to elicit a complete antioxidant enzyme response. Therefore, we investigated whether Dar induced significant levels of HO-1, the prototypic arsenic-induced phase II antioxidant enzyme. Figure 1b shows that Dar did not induce HO-1 protein expression in any of the tested cell lines, as opposed to ATO that strongly induced expression in all cell lines. We were able to reproduce these results in HeLa cells, suggesting that our results are not limited to hematological malignancies (Figures 1a and b) . To verify this observation, we treated both NB4 and U937 cells with ATO or Dar and assessed HMOX1 mRNA levels by quantitative PCR (qPCR). Treatment with Dar failed to induce significant HMOX1 expression in either cell line. This result remained consistent in NB4 ( Figure 1c ) and U937 (Figure 1d Figure 2C) . Our data indicate that the activation of HO-1 expression in response to NRF2 signaling is different than for the other NRF2 target genes.
Dar is more toxic than ATO and does not induce HO-1 in APL cells from patients Although we show that Dar fails to induce HO-1 expression in several cell lines, we wanted to confirm these findings with primary APL blasts, the only malignancy in which ATO has proven to hold clinical benefit. Therefore, blasts were obtained from APL patients, and were treated ex vivo with ATO and Dar. Dar induces more cell death as shown by cell viability assay and caspase-3 activity assay (Figures 3a and b) . We also quantified HMOX1 mRNA levels in response to ATO and Dar. Figure 3c shows that even though ATO treatment induced significant HMOX1 expression, Dar treatment was not followed by an increase in HMOX1 mRNA levels, regardless of dose. As shown in Figure 3d , Dar treatment led to increased TXNRD1 mRNA levels in APL patient blasts treated ex vivo, confirming in patient cells the results obtained in cell lines wherein HO-1 is the only NRF2 target gene not induced by Dar. This suggests that this surprising observation is relevant in vivo. Dar does not induce the recruitment of BRG1, a necessary transcription coactivator, at the HMOX1 promoter We sought to investigate the mechanism for the selective failure of Dar to activate HMOX1. HMOX1 is a well-known target gene for the transcription factor NRF2. Therefore, we investigated whether Dar failed to induce HMOX1 expression because of an altered Darinaparsin prevents heme oxygenase-1 induction N Garnier et al Figure 1 . Dar is more toxic than ATO and fails to induce HO-1 in various malignant cell lines. Cells from various cell lines were treated with equimolar concentrations of ATO and Dar (2 or 5 mM) for 24 h. Cell death was then quantified by propidium iodide staining followed by FACS analysis (a), and HO-1 protein levels were quantified by western blot (b). NB4 cells were treated with 1 and 2 mM ATO or Dar for 6 h (c), or 2 mM ATO or Dar for 3 and 6 h (d). HMOX1 mRNA levels were quantified by reverse transcriptase-qPCR. HMOX1 mRNA levels were also quantified in U937 cells after ATO or Dar treatment (dose response at 6 h (c left and d left) and time course at 2 mM (c right and d right). *Po0.05, **Po0.001, ***Po0.001.
Darinaparsin prevents heme oxygenase-1 induction N Garnier et al NRF2-signaling pathway. We first examined an early event in NRF2 signaling, the translocation of NRF2 from the cytoplasm to the nucleus. We treated NB4 cells with ATO and Dar, and then performed western blot analyses of the protein content of the cytoplasm versus nucleus. As shown in Figure 4a , both ATO and Dar induce NRF2 stabilization and translocation to the nucleus, in a time-dependent manner. This confirms that NRF2 is competent to signal after Dar treatment, as indicated by upregulation of TR1, NQO1 and gGCS. In addition, we examined whether ATO or Dar altered expression of a heterodimer partner of NRF2, the Small Maf protein G (sMafG). sMafs are required for NRF2 binding to AREs, and activation of target genes. 24 Figure 4a shows that sMafG 25 protein levels in the nucleus did not vary between ATO and Dar treatment.
Next, we focused on whether NRF2 signaling at the HMOX1 promoter was impaired. We investigated the events at the HMOX1 AREs subsequent to treatment with ATO or Dar. In the presence of intracellular ROS, BACH1 is released from the AREs and NRF2 is recruited to the AREs. 22, 26 Therefore, we performed ChIP assays in NB4 cells treated with ATO or Dar and assessed binding of BACH1 and NRF2 to both the 9 kb and the 3 kb AREs. 22 Both ATO and Dar caused BACH1 release from AREs in HMOX1 and TXNRD1's promoters (Figure 4b) . A lesser effect was observed at the TXNRD1 ARE, which is consistent with a minor role for BACH1 in the regulation of TXNRD1 transcription. 26 Moreover, both ATO and Dar led to NRF2 binding to HMOX1 and TXNRD1 AREs (Figure 4c ). However, NRF2 recruitment to HMOX1's AREs is significantly less after Dar treatment compared with ATO ( Figure 4c ). In contrast, we observed NRF2 recruitment at the TXNRD1 ARE after treatment with either ATO or Dar (Figure 4c ), indicating that the decreased NRF2 recruitment to the HMOX1 ARE is specific.
HMOX1 transcriptional activation is distinct from other NRF2 targets, because it further requires the recruitment of BRG1 to the promoter. BRG1 exhibits helicase activity and is able to fold the chromatin, leading to a Z-DNA structure, in which BRG1 interacts with AREs at À 3 kb and À 9 kb of the HMOX1 promoter region. Only then can transcription be initiated. 23 We assessed BRG1 binding at the HMOX1 AREs subsequent to treatment with ATO or Dar. As shown in Figure 4d , ATO recruits BRG1 to HMOX1 AREs, whereas Dar treatment fails to recruit BRG1. Neither ATO nor Dar recruit BRG1 to the TXNRD1 ARE, which is expected as BRG1 is not required for TXNRD1 transcription, and confirms the specificity of our findings at the HMOX1 AREs. Enrichment of BACH1, NRF2 and BRG1 was assessed at a distal site of the chromosome 12 throughout these procedures, as a negative control. We showed no enrichment, confirming specificity of binding to AREs reported in this figure. Together, our results suggest that NRF2 signaling that is induced by Dar lacks an essential step, involving BRG1, which is specifically required for the activation of HMOX1.
Dar causes G2/M arrest leading to BRG1 phosphorylation, which prevents it from being recruited to the HMOX1 promoter Investigating the events leading to aborted HMOX1 activation in cells treated with Dar, we found that BRG1 is not recruited to the HMOX1 promoter upon Dar treatment. However, ATO induces BRG1 recruitment, allowing HMOX1 expression. Therefore, regulation of BRG1 differs between ATO and Dar. Another difference between ATO and Dar is their effects on the cell cycle. ATO can induce a G1 cell cycle arrest, 27 whereas Dar induces a G2/M arrest.
1,2 Figure 5a shows that ATO causes NB4 cells to accumulate in the G1 phase of the cell cycle, whereas Dar causes a G2/M accumulation. We therefore postulated that these two distinct features, in response to two arsenicals, might be related. In fact, Figure 4 . Dar does not induce the recruitment of BRG1, a necessary transcription coactivator, at the HMOX1 promoter. NB4 cells were treated for 1, 3 and 6 h with 2 mM ATO or Dar. Nuclear and cytoplasmic protein levels were quantified after cyto-nuclear fractionation followed by western blot (a). Intensities of NRF2 bands, measured by densitometry, are indicated as arbitrary units below the figure. NB4 cells were treated with 2 mM ATO or Dar for 3 h, ChIP for BACH1 (b), NRF2 (c) and BRG1 (d) at the À 3 kb HMOX1 ARE, at the À 9 kb HMOX1 ARE and at the TXNRD1 ARE, and at a chromosome 12 distal site followed by qPCR analysis, were then performed. *Po0.05, **Po0.01, ***Po0.001. We next investigated the link between cell cycle and BRG1 regulation. BRG1 is regulated via phosphorylation, which can occur either during the M phase of the cell cycle 28, 29 or upon DNA damage. 30, 31 Phosphorylation of BRG1 leads to its inactivation and exclusion from the chromatin. 28, 29 We therefore hypothesize that synchronizing cells in G2/M with nocodazole leads to BRG1 hyperphosphorylation, 28 rendering HO-1 induction impossible. Accordingly, Dar, but not ATO, induces BRG1 phosphorylation, as indicated by western blot analysis after separation by SDSpolyacrylamide gel electrophoresis. The mobility of BRG1 was slower in Dar-treated cell extracts than in ATO or untreated cell extracts (Figure 5c ). The slower mobility of BRG1 in Dar-treated extracts is similar to what was observed by other groups. 28, 29 Lambda-phosphatase treatment shifted the migration of the Dar-treated BRG1 proteins to that of untreated or ATO-treated cell extracts (Figure 5c ), supporting our hypothesis that the slower migrating BRG1 band is a phosphorylated form of BRG1. Nocodazole was used as a positive control for G2/M arrestmediated BRG1 phosphorylation. Together, these results argue strongly that the mobility shift we observed was due to changes in the phosphorylation pattern of BRG1 upon Dar treatment. These data support the hypothesis that Dar causes BRG1 phosphorylation through G2/M cell cycle arrest, and that BRG1 phosphorylation prevents an essential step for HMOX1 transcription.
Next, we asked whether Dar could prevent HO-1 activation by ATO. Figure 5d shows that cells synchronized in G2/M by Dar mostly remain in G2/M when subsequently treated with ATO. Moreover, in cells treated with Dar before ATO, BRG1 is neither Figure 5 . Dar causes G2/M arrest, leading to BRG1 phosphorylation and inactivation, which prevents HO-1 induction. NB4 cells were treated with 2 mM ATO or Dar for 18 h, or with 3 mM aphidicolin or 0.3 mM nocodazole for 12 h, with or without 2 mM ATO or Dar for 6 additional hours, then stained with propidium iodide. Cell cycle was analyzed by flow cytometry (a). NB4 cells were treated with 2 mM ATO or Dar for 18 h or with 3 mM aphidicolin or 0.3 mM nocodazole for 12 h, with or without 2 mM ATO or Dar for 6 additional hours. HO-1 protein levels were assessed by western blot (b). NB4 cells were treated for 3 h with 2 mM ATO or Dar, and migration of BRG1 was assessed by western blot. Dar-treated extract was incubated for 1 h with phosphatase lambda at 37 1C (lane 4). Nocodazole (0.3 mM) was used as a positive control for phosphorylation of BRG1 (c). NB4 cells were treated with 2 mM ATO or Dar for 18 h, or with 2 mM Dar for 12 h, and 2 mM ATO for 6 additional hours, and then stained with propidium iodide. Cell cycle was analyzed by flow cytometry (d). NB4 cells were treated with 2 mM ATO or Dar for 3 h, or for 3 h with Dar and 3 additional hours with ATO. ChIP for BRG1 at the À 3 kb HMOX1 ARE and at the À 9 kb HMOX1 ARE, followed by qPCR analysis, were then performed (e). NB4 cells were treated with 2 mM ATO or Dar for 6 h, or for 3 h with Dar and 3 additional hours with ATO. HMOX1 mRNA levels (f ) and protein levels (g) were assessed. ***Po0.001.
recruited to the HMOX1 AREs (Figure 5e ), nor do they show increased HMOX1 mRNA levels (Figure 5f ). Consistent with this, pre-treatment with Dar prevents ATO from inducing an increase in HO-1 protein levels (Figure 5g, lane 4, D-A) . This suggests that impairment of HMOX1 expression by Dar is an active process.
HO-1 is partially responsible for limiting the cytotoxicity of ATO The induction of HO-1 by ATO and other ROS inducers has been reported to be cytoprotective in some malignant cell lines. 16 We wanted to address whether or not inhibiting HO-1 could enhance ATO-induced apoptosis. To this end, we utilized a selective inhibitor of the HO-1 enzyme, OB-24. 32 We treated NB4 (Figure 6a ) or U937 (Figure 6b ) cells with ATO or Dar with or without concomitant treatment with OB-24. We show that OB-24 can enhance significantly the toxicity of ATO towards leukemic cells, supporting a cytoprotective role of HO-1. In contrast, OB-24 induces no change in the level of Dar-induced apoptosis, where HO-1 is not induced. To validate these pharmacological results, we silenced HMOX1 using lentiviral short hairpin RNA (shRNA) in NB4 cells. Figure 6c shows by western blot analysis that the shRNA led to lower HO-1 induction by ATO. Figure 6d shows that NB4 cells transfected with HMOX1 shRNA are more sensitive to ATO than NB4 cells transfected with non-target shRNA. Genetically silencing HMOX1 did not alter Dar-induced apoptosis. That was to be expected as Dar does not lead to HMOX1 expression, and suggests that the enhanced efficacy of Dar is partially because of the absence of HO-1 induction. To test the role of BRG1 in HO-1 induction, we silenced BRG1 using lentiviral shRNA in NB4 cells. Figure 6e shows by western blot that the knockdown of BRG1 reduces ATO-induced HO-1 expression. In addition, NB4 cells transfected with BRG1 shRNA are more sensitive to ATO-induced apoptosis, whereas they remain sensitive to Dar. Taken together, these results strongly suggest that BRG1 is required for the cytoprotective HO-1 induction upon ATO treatment.
DISCUSSION
We investigated the response of cancer cells to a new arsenicbased, anticancer drug, Dar. We found an unexpected selective regulation of NRF2 target genes between ATO and Dar. HMOX1 stands out among the NRF2 targets tested as the sole gene not induced by Dar. This is unexpected, considering the fact that HO-1 levels are commonly used as a marker for intracellular ROS. It is Figure 6 . Dar is more toxic than ATO because it does not induce HO-1. NB4 (a) and U937 (b) cells were treated with 1 mM ATO or Dar, with or without 100 mM (NB4) or 20 mM (U937) OB-24 for 24 h. Cell death was then quantified by propidium iodide staining followed by FACS analysis. NB4 cells expressing non-targeted shRNA or shRNA against HMOX1 (c) or SMARCA4 (e) were treated with 2 mM ATO for 6 h. Protein levels were quantified by western blot. NB4 cells expressing non-targeted shRNA or shRNA against HMOX1 (d) or SMARCA4 (f ) were treated with 2 mM ATO or Dar for 24 h. Cell death was then quantified by propidium iodide staining followed by FACS analysis. **Po0.01, ***Po0.001. more surprising that ROS can lead to specific differential responses from the cell, considering that a given ROS does not bear the mark of its origin. Previous work reported that indeed Dar does not induce HMOX1 transcription in a multiple myeloma model, where other NRF2 target genes regulated by AREs were also not induced by Dar. 33 In our system, Dar can induce NRF2 target genes regulated via AREs other than HMOX1. In fact, Dar induces more expression of TR1, NQO1 and gGCS, but not enough to confer a cytoprotective response. This is consistent with the fact that, for example, diminution of intracellular levels of glutathione (GSH) by inhibition of gGCS with buthionine sulfoximine does not increase Dar-induced apoptosis. Moreover, ATO-resistant cells have higher levels of gGCS, hence of intracellular GSH than their sensitive counterparts, but remain sensitive to Dar.
2 NQO1 induction can be transient. We detected induction of NQO1 by Dar 3 and 6 h after treatment, whereas previous work was performed at 24 h. 33 In addition, Matulis et al., showed that Dar did not induce activation of a reporter gene downstream of a consensus ARE. 33 Our data, as well as the work of others, suggest that the chromatin context, the presence/absence of coregulators, the chromosomal localization and the genes regulated by the ARE studied are crucial determinants of the 34 -specificity of BACH1/ NRF2 binding to a given ARE and 1 -specificity of the response toward a given stress inducer. 26 Here, we propose a mechanistic model for the differential induction of HO-1 by arsenicals. We hypothesize that the lack of HO-1 activation is partially responsible for Dar-enhanced antitumor properties. As described in Figure 7 , both ATO and Dar can initiate the canonical NRF2-signaling cascade, causing BACH1 to be released from the AREs and NRF2 to be recruited to these AREs. However, Dar also induces hyperphosphorylation of BRG1, preventing BRG1 from participating in the induction of HO-1. This correlates with the ability of Dar to induce G2/M cell cycle arrest, during which BRG1 is phosphorylated and excluded from the chromatin. 29 Accordingly, G2/M arrest related DNA-repair machinery, represented by DNApK and ATM, is activated by Dar, as shown in Supplementary Figure 7. To date, no evidence shows that DNA damage induced by ATO or Dar differs. However, other reports suggest that rapid activation of ATM followed by early induction of apoptosis can be associated with chromatin decondensation. 35 Future efforts will be directed towards investigating these potential mechanistic differences.
Among all NRF2 target genes, HMOX1 regulation is unique and includes more levels of complexity. Although NRF2 binding to AREs is required, BRG1 is also needed. 23 Dar treatment fails to recruit NRF2 to the same levels as ATO. One possibility is that BRG1 is required to stabilize NRF2 binding at HMOX1 AREs in our model. It is also possible that Z-DNA formation, promoted by BRG1, would enhance NRF2 binding. However, data from Zhang et al. 23 indicate that NRF2 binding is independent of BRG1 recruitment using shRNA knockdown of BRG1 in the SW480 human colon adenocarcinoma cell line. The role of BRG1 in AML cells may differ, and/or full knockout of BRG1 may destabilize NRF2 at the HMOX1 promoter. Alternatively, maximal NRF2 binding at AREs may be necessary for BRG1 recruitment. Titrated knockdown of NRF2 in AML cells may define levels of NRF2 required for BRG1 recruitment and HMOX1 expression. We have confirmed that ATO, but not Dar, induces HMOX1 in cell lines derived from multiple cell types. Importantly, both ATO and Dar activate several other NRF2 target genes in APL and non-APL cell lines. This suggests that multiple cell types respond to Darinduced gene expression in a similar manner. However, it is possible that alternative mechanisms can also lead to the lack of HMOX1 gene activation. Clearly, pathways other than NRF2 may be differentially regulated by ATO and Dar and lead to the antiapoptotic feedback induced by ATO. Activation of p38 MAPK, ERK and the Akt-mTOR pathways have been proposed to counteract ATO-induced cell death. 36 The impact of Dar treatment on these other negative feedback pathways induced by ATO might bring new insights to the mechanisms underlying Dar's enhanced efficacy.
HO-1 is widely considered as cytoprotective through handling of free heme. Intracellular accumulation of free heme occurs when, in the presence of ROS, hemoproteins release it. The combination of ROS and free heme is cytotoxic, because the latter promotes further ROS production through the Fenton reaction. HO-1 not only inactivates free heme, but by doing so, also promotes the synthesis of antioxidant agents, including billirubin, iron (Fe) stored in L-ferritin (Fe/FtL) and carbon monoxide. 16, [37] [38] [39] HO-1 is extensively studied for its cytoprotective effects, 16 and we present evidence that HO-1 is cytoprotective in malignant cell lines. In contrast to our observations, it should be noted that under some conditions, HO-1 has been reported to be cytotoxic. 16 Iron released from free heme by the action of HO-1 can, if not stored in Fe/FtL, lead to cytotoxicity through the Fenton reaction.
HO-1 has been proposed to promote cancer progression and angiogenesis. 32 This has led to the development of a selective inhibitor of the HO-1 enzyme, the imidazole derivative OB-24. 32 Alaoui-Jamali et al. 32 showed that OB-24 specifically inhibits the activity of HO-1 in a human advanced prostate cancer cell line Figure 7 . Differential regulation of the NRF2 response battery by ATO and Dar. Under normal conditions, NRF2 is sequestered in the cytoplasm and its target genes are repressed by BACH1. ATO and Dar induce ROS, which causes the release of NRF2 from sequestration in the cytoplasm and subsequent translocation to the nucleus. NRF2 binds to the AREs of its targets to induce gene expression. HMOX1 activation requires an additional step that consists of the recruitment of BRG1. Dar induces BRG1 phosphorylation that prevents recruitment to the ARE.
in vitro and in intact mice. In our model, OB-24 enhances ATOinduced cytotoxicity. This is consistent with our hypothesis that the lack of HO-1 expression subsequent to Dar treatment has a role in Dar's greater antitumor potential compared with ATO.
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